CN114712311A - 一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 - Google Patents
一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 Download PDFInfo
- Publication number
- CN114712311A CN114712311A CN202210398535.3A CN202210398535A CN114712311A CN 114712311 A CN114712311 A CN 114712311A CN 202210398535 A CN202210398535 A CN 202210398535A CN 114712311 A CN114712311 A CN 114712311A
- Authority
- CN
- China
- Prior art keywords
- self
- silk fibroin
- baicalein
- silk
- fibroin peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010022355 Fibroins Proteins 0.000 title claims abstract description 55
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title claims abstract description 33
- 210000003734 kidney Anatomy 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 9
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims abstract description 28
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940015301 baicalein Drugs 0.000 claims abstract description 26
- 229960004316 cisplatin Drugs 0.000 claims abstract description 22
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 206010061481 Renal injury Diseases 0.000 claims abstract description 15
- 208000037806 kidney injury Diseases 0.000 claims abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 11
- 239000001110 calcium chloride Substances 0.000 claims abstract description 11
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 9
- 238000001338 self-assembly Methods 0.000 claims abstract description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- 241000699670 Mus sp. Species 0.000 claims description 10
- 108010013296 Sericins Proteins 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 229940109239 creatinine Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- -1 tissue repair Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210398535.3A CN114712311B (zh) | 2022-04-15 | 2022-04-15 | 一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210398535.3A CN114712311B (zh) | 2022-04-15 | 2022-04-15 | 一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114712311A true CN114712311A (zh) | 2022-07-08 |
CN114712311B CN114712311B (zh) | 2023-05-23 |
Family
ID=82243788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210398535.3A Active CN114712311B (zh) | 2022-04-15 | 2022-04-15 | 一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114712311B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115444818A (zh) * | 2022-08-12 | 2022-12-09 | 青岛科技大学 | 一种基于丝素蛋白纳米纤维的滴眼药物增溶辅料及含该辅料药物的制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5566929A (en) * | 1978-11-13 | 1980-05-20 | Kanebo Ltd | Finely-powdered fibroin and its manufacture |
JPH01254621A (ja) * | 1988-04-01 | 1989-10-11 | Terumo Corp | 薬剤担体および徐放性薬剤ならびにそれらの製造方法 |
US20110305765A1 (en) * | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
WO2015144056A1 (zh) * | 2014-03-27 | 2015-10-01 | 苏州丝美特生物技术有限公司 | 一种大分子量丝素蛋白冻干粉、制备工艺及其应用 |
CN107157952A (zh) * | 2017-06-30 | 2017-09-15 | 广东工业大学 | 一种丝素蛋白纳米粒和载药丝素蛋白纳米粒 |
CN109482153A (zh) * | 2018-11-30 | 2019-03-19 | 广西科技大学 | 一种基于紫外共价交联的丝素固定化dna吸附剂制备方法及其在黄曲霉毒素消除中的应用 |
CN110368365A (zh) * | 2019-08-13 | 2019-10-25 | 西南大学 | 一种含pf127的丝素载药纳米粒子的制备方法 |
CN111803632A (zh) * | 2019-04-09 | 2020-10-23 | 北京五和博澳药业有限公司 | 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途 |
WO2022028396A1 (zh) * | 2020-08-06 | 2022-02-10 | 苏州大学 | 一种蚕丝抗凝血管支架覆膜及其制备方法 |
WO2022040517A1 (en) * | 2020-08-21 | 2022-02-24 | University Of Florida Research Foundation, Incorporated | Silk particles encapsulating oxygen carriers as artificial blood substitute |
-
2022
- 2022-04-15 CN CN202210398535.3A patent/CN114712311B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5566929A (en) * | 1978-11-13 | 1980-05-20 | Kanebo Ltd | Finely-powdered fibroin and its manufacture |
JPH01254621A (ja) * | 1988-04-01 | 1989-10-11 | Terumo Corp | 薬剤担体および徐放性薬剤ならびにそれらの製造方法 |
US20110305765A1 (en) * | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
WO2015144056A1 (zh) * | 2014-03-27 | 2015-10-01 | 苏州丝美特生物技术有限公司 | 一种大分子量丝素蛋白冻干粉、制备工艺及其应用 |
CN107157952A (zh) * | 2017-06-30 | 2017-09-15 | 广东工业大学 | 一种丝素蛋白纳米粒和载药丝素蛋白纳米粒 |
CN109482153A (zh) * | 2018-11-30 | 2019-03-19 | 广西科技大学 | 一种基于紫外共价交联的丝素固定化dna吸附剂制备方法及其在黄曲霉毒素消除中的应用 |
CN111803632A (zh) * | 2019-04-09 | 2020-10-23 | 北京五和博澳药业有限公司 | 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途 |
CN110368365A (zh) * | 2019-08-13 | 2019-10-25 | 西南大学 | 一种含pf127的丝素载药纳米粒子的制备方法 |
WO2022028396A1 (zh) * | 2020-08-06 | 2022-02-10 | 苏州大学 | 一种蚕丝抗凝血管支架覆膜及其制备方法 |
WO2022040517A1 (en) * | 2020-08-21 | 2022-02-24 | University Of Florida Research Foundation, Incorporated | Silk particles encapsulating oxygen carriers as artificial blood substitute |
Non-Patent Citations (2)
Title |
---|
ANTONIO ABEL LOZANOPÉREZ ET AL.: "Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats" * |
蔡维: "检索记录" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115444818A (zh) * | 2022-08-12 | 2022-12-09 | 青岛科技大学 | 一种基于丝素蛋白纳米纤维的滴眼药物增溶辅料及含该辅料药物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114712311B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111870579B (zh) | 一种肿瘤靶向纳米胶束、制备方法及作为药物载体的应用 | |
CN108310395A (zh) | 一种表面电荷可转换的聚合物纳米药物载体及制备方法和应用 | |
Gou et al. | Advances and prospects of Bletilla striata polysaccharide as promising multifunctional biomedical materials | |
CN114712311B (zh) | 一种丝素蛋白肽自组装载药纳米粒的制备及其肾保护作用 | |
CN102408560B (zh) | 一种环境响应型星形共聚物的制备方法 | |
CN101984958A (zh) | 纳米级阿苯达唑微粉及其制备方法 | |
Ma et al. | Crosslinked zwitterionic microcapsules to overcome gastrointestinal barriers for oral insulin delivery | |
CN107266384A (zh) | 基于2‑氨基十六烷酸的n‑羧基内酸酐单体和聚氨基酸及其制备方法 | |
CN114588275A (zh) | 一种具有脑靶向性的细胞膜仿生修饰药物纳米晶及其制备方法与应用 | |
CN104434792A (zh) | 聚合物胶束及其制备方法和抗肿瘤药物组合物、制剂及其制备方法 | |
CN105879048B (zh) | 基于聚氨基酸的功能性生物可降解纳米粒子的制备方法 | |
CN115581707B (zh) | 一种壳寡糖-姜黄素纳米复合体的制备方法 | |
CN109662956B (zh) | 一种齐墩果酸接枝的壳聚糖载药纳米颗粒的应用 | |
CN111494318A (zh) | 一种肿瘤靶向和还原敏感型复合胶束及其制备方法和应用 | |
CN114642652B (zh) | 一种岩藻多糖自组装载药纳米粒制备及应用 | |
CN114652699B (zh) | 一种尺寸转变型纳米递药载体及其制备方法和应用 | |
CN113577308A (zh) | 缺血性脑卒中靶向治疗用纳米载药系统及其制备方法 | |
CN104672441B (zh) | 聚乙二醇-硫基辛酸-维生素e共聚物及制备方法和应用 | |
CN114533671A (zh) | 基于生物可降解超支化聚碳酸酯“壳-核”式聚合物胶束的制备方法及应用 | |
CN112057632A (zh) | 一种复合型阿霉素脂质体及其制备方法 | |
CN110498877A (zh) | 聚(2-羧基丙烯酸)及其制备方法和应用 | |
CN114432243B (zh) | 一种响应pH和葡萄糖的纳米载体及其应用 | |
CN113603811B (zh) | 一种pH敏感和氧增敏的透明质酸氟化聚合物及其合成方法与应用 | |
CN111888340B (zh) | 一种pH响应缓释的含硒蛋白复合纳米粒子及制备与应用 | |
CN116869950B (zh) | 一种降血压生物降解皮下埋植棒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240520 Address after: Room 1018-15, Building 23, Times Square, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou 30 billion Technology Co.,Ltd. Country or region after: China Address before: 266000 Songling Road, Laoshan District, Qingdao, Shandong Province, No. 99 Patentee before: QINGDAO University OF SCIENCE AND TECHNOLOGY Country or region before: China |
|
TR01 | Transfer of patent right |